There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ChemoCentryx (CCXI), Y-Mabs Therapeutics (YMAB) and Summit Therapeutics (SMMT) with bullish sentiments.
ChemoCentryx (CCXI)
Canaccord Genuity analyst Michelle Gilson maintained a Buy rating on ChemoCentryx yesterday and set a price target of $75.00. The company’s shares closed last Tuesday at $61.95, close to its 52-week high of $63.78.
According to TipRanks.com, Gilson is a 5-star analyst with an average return of 33.2% and a 59.4% success rate. Gilson covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Eloxx Pharmaceuticals, and Homology Medicines.
ChemoCentryx has an analyst consensus of Strong Buy, with a price target consensus of $70.17, representing a 14.3% upside. In a report issued on May 18, H.C. Wainwright also reiterated a Buy rating on the stock with a $69.00 price target.
See today’s analyst top recommended stocks >>
Y-Mabs Therapeutics (YMAB)
Canaccord Genuity analyst Arlinda Lee maintained a Buy rating on Y-Mabs Therapeutics yesterday and set a price target of $48.00. The company’s shares closed last Tuesday at $42.37, close to its 52-week high of $43.80.
According to TipRanks.com, Lee is a 4-star analyst with an average return of 3.6% and a 49.0% success rate. Lee covers the Healthcare sector, focusing on stocks such as Turning Point Therapeutics, Black Diamond Therapeutics, and Deciphera Pharmaceuticals.
Currently, the analyst consensus on Y-Mabs Therapeutics is a Strong Buy with an average price target of $48.00, a 10.7% upside from current levels. In a report issued on June 1, H.C. Wainwright also reiterated a Buy rating on the stock with a $52.00 price target.
Summit Therapeutics (SMMT)
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Summit Therapeutics today and set a price target of $4.00. The company’s shares closed last Tuesday at $3.75.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 13.6% and a 43.4% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Aurinia Pharmaceuticals.
Currently, the analyst consensus on Summit Therapeutics is a Moderate Buy with an average price target of $4.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
